Gene therapy study for hearing loss caused by OTOF gene mutation
Part of Brain & nervous system, Ear, nose & throat clinical trials.
This trial tests a gene therapy called EH002 for people with severe or profound hearing loss due to changes in the OTOF gene. The treatment aims to help the ear hear better by replacing the faulty gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have severe or profound hearing loss (hearing threshold of 65 dB or greater).
- A genetic test must show a mutation in the OTOF gene (the type that causes DFNB9 deafness).
- You must be at least 6 months old.
- An ear CT or MRI must show that your ear structure and hearing nerve are normal and that surgery is safe.
- You cannot have other ear problems, like chronic ear infections, or have had a cochlear implant in the ear being treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children with hearing loss caused by changes in specific genes (GJB2 or OTOF). It helps researchers understand how hearing develops over time and how children may do with or without cochlear implants.
This study is developing a system to evaluate and improve hearing for people with congenital hearing loss. It compares participants who have hearing loss (and have used hearing aids, cochlear implants, or gene therapy) with healthy controls, to better understand and treat hearing challenges.
This trial tests delivering gene therapy into the inner-ear hearing balance nerve cells during surgery for vestibular schwannoma. It may help by improving how the inner ear functions after tumor removal, but you must meet several specific surgery and safety requirements.
This trial tests a one-time gene therapy delivered into the ear to improve hearing in people with certain OTOF gene changes. It studies safety and how well the treatment can work, especially in children and infants, as doctors monitor hearing tests for up to 48 weeks.
This trial tests an injection called EHT102 for children who have severe or profound hearing loss due to mutations in the Otoferlin gene. The goal is to see if the treatment can restore or improve hearing.
This early-stage study tests a one-time gene therapy to help patients with profound hearing loss linked to otoferlin gene mutations. It may help hearing by delivering a working version of the otoferlin gene to the inner ear, followed by long-term monitoring.
Hear when a new Congenital Hearing Loss trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.